Imatinib – First-Line Tyrosine Kinase Inhibitor Therapy
Imatinib is an oral, first-in-class, small-molecule targeted protein tyrosine kinase inhibitor that revolutionized the management of hematologic malignancies. The drug was developed to highly selectively block the activity of the BCR-ABL tyrosine kinase, which is formed as a result of a reciprocal translocation between chromosomes 9 and 22 (the Philadelphia chromosome, Ph+). The mechanism of action of imatinib involves competitive binding to the ATP-binding pocket of the BCR-ABL kinase domain, preventing phosphate group transfer to substrates, disrupting downstream signaling cascades, and inducing apoptosis in Ph-positive tumor cells. In addition to BCR-ABL, imatinib effectively inhibits receptor tyrosine kinases for stem cell factor (c-KIT / CD117), platelet-derived growth factor receptors (PDGFR-alpha and PDGFR-beta), and macrophage colony-stimulating factor (CSF-1R).
The clinical uniqueness of imatinib lies in its capacity to transform a once-fatal disease like chronic myeloid leukemia into a manageable, chronic somatic condition with long-term patient survival. The drug also demonstrated exceptional efficacy in gastrointestinal stromal tumors (GIST), where activating mutations in the c-KIT gene serve as the primary oncogenic driver of interstitial cells of Cajal. Imatinib displays high oral bioavailability (approximately 98%), reaching peak plasma concentrations within 2 to 4 hours. It is primarily metabolized in the liver by the CYP3A4 isoenzyme to form its active N-demethylated metabolite and is excreted predominantly in the feces as metabolites.
The drug is administered orally. Prior to initiating treatment, cytogenetic or molecular-genetic confirmation of the Philadelphia chromosome or c-KIT expression is mandatory. Regular monitoring of peripheral blood counts and hepatic function is required throughout therapy.
Indications
Imatinib is indicated for the targeted treatment of adult and pediatric patients with the following oncological and hematological conditions:
- Chronic Myeloid Leukemia (CML): treatment of newly diagnosed Ph-positive chronic myeloid leukemia in adult and pediatric patients, as well as CML in accelerated phase or blast crisis after failure or intolerance of prior interferon-alpha therapy.
- Acute Lymphoblastic Leukemia (ALL): integrated with chemotherapy for adult and pediatric patients with newly diagnosed Ph-positive ALL, or as monotherapy for relapsed or refractory Ph-positive ALL.
- Gastrointestinal Stromal Tumors (GIST): treatment of adult patients with KIT-positive (CD117) unresectable and/or metastatic gastrointestinal stromal tumors, and adjuvant therapy of adult patients following radical resection of GIST at high risk of recurrence.
- Other Rare Pathologies: treatment of adult patients with dermatofibrosarcoma protuberans (DFSP), hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL), and myelodysplastic/myeloproliferative diseases associated with PDGFR gene rearrangements.
Dosage and administration
The dosing regimen of imatinib is continuous and determined by the specific disease entity, clinical phase, and the patient's body weight.
- Standard Doses: for CML in chronic phase and GIST, the recommended adult dose is 400 mg orally once daily. For accelerated phase or blast crisis of CML, the dose is increased to 600 mg or 800 mg daily (the 800 mg dose is split into two 400 mg administrations, morning and evening).
- Pediatric Dosing: for CML and ALL, pediatric dosing is calculated based on body surface area, with a standard dose of 340 mg/m² daily (not to exceed the maximum adult daily dose).
- Administration Method: tablets or capsules should be taken orally with a meal and a large glass of water to minimize the risk of gastrointestinal irritation. Tablets must not be chewed, but for patients with dysphagia, they can be dispersed in water or apple juice.
- Missed Dose: if a dose is missed, the patient should skip the missed dose and resume the regular schedule the following day; a double dose should never be taken to compensate.
- Dose Modification: in the event of severe hematological toxicity (neutropenia <1.0x10⁹/L, thrombocytopenia <50x10⁹/L), therapy should be withheld until recovery, followed by a potential dose reduction (e.g., from 400 mg to 300 mg).
